Netramark Holdings Inc · TSX:AIAI
Netramark — Investor Presentation (April 2025)
27 slides from Netramark's investor presentation, April 2025
Slide 1: Corporate Presentation
CSE: AIAI OTCQB : AINMF C O R P O R AT E P R E S E N TAT I O N FRA: PF0
Slide 2: Disclaimer
IMPORTANT – YOU MUST READ THE FOLLOWING BEFORE CONTINUING: The information contained in this presentation has been CAUTIONARY NOTE REGARDING FUTURE-ORIENTED FINANCIAL INFORMATION: To the extent any forward-looking statement in this presentation prepared by NetraMark Holdings Inc. (“NetraMark” or the
Slide 3: Risk Factors
RISK FACTORS: There are a number of risk factors as set out below that could cause future results of the Company to differ materially from those described herein. The risks and uncertainties described herein are not the only ones the Company faces. Additional risks and uncertainties, including those
Slide 4: NetraMark: We Optimize Response Prediction
We Optimize Response Prediction Netra is derived from Sanskrit and means “Eyes” NETRAMARK We leverage a Sponsor’s clinical trial data readouts using our proprietary AI to identify subpopulations driving drug response, placebo response and adverse events and inform subsequent trial strategies. The Ne
Slide 5: Regulatory Guidance for Clinical Trial Enrichment Pre-Randomization
Regulatory Guidance for Clinical Trial Enrichment Pre-Randomization Regulator Support for Enrichment Strategies if: • Reduce Variability: Select patients based on consistent baseline measures to minimize variability within the study population. R E G U L AT O R Y A L I G N M E N T • Enhance Prognosi
Slide 6: The Problem: Only 12% of candidate medicines are approved
Only 12% of candidate medicines are approved by the FDA – there is a lot of ”at risk” capital BASIC DRUG PRE- FDA POST-APPROVAL DISCOVERY CLINICAL TRIALS RESEARCH & MONITORING RESEARCH CLINICAL REVIEW PHASE 1 PHASE 2 PHASE 3 PHASE IV From drug discovery through FDA approval, developing a new FDA med
Slide 7: Why do so few candidate medicines survive the clinical trial process?
Why do so few candidate medicines survive the clinical trial process? Core Challenges – Expensive pivotal trials fail for the following reasons: • Noise from the expanded Phase 3 study population distorted the signal THE PROBLEM • Wrong Endpoint measure not suited to the population • Questionable cl
Slide 8: The Market: clinical trial market is robust, growing and large
The clinical trial market is robust, growing and large The number of cumulative clinical trials over time1 Global Clinical Trial Support Services (in USD Billions)2 450,000 399,522 400,000 362,500 50.0 325,771 R 350,000 45.0 C AG % 300,000 293,254 40.0 7.2 262,299 35.0 250,000 233,124 30.0 205,335 2
Slide 9: The Clinical Trial AI Landscape
How is the Pharmaceutical industry leveraging AI in clinical trials? Competitive AI application area Competitive AI application area Clinical Trial Operations Protocol Basic Drug Data THE CINICAL TRIAL AI LANDSCAPE Research Discovery Readout Protocol Data Readout Less competitive AI application area
Slide 10: The Challenges
To overcome key trial related risks a Sponsor must maximize their understanding of their clinical trial data readouts to clearly understand which variables are behind elevated trial risk Clinical Trial Data Readout THE CHALLENGES Number of variables collected per patient 1,000 Number of patients 1.3
Slide 11: The Solution – How NetraMark's Technology Works
The solution and advantages of NetraMark’s proprietary AI THE SOLUTION – HOW NETRAMARK’S TECHNOLOGY WORKS • Has the ability to uniquely leverage small clinical trial data sets, which is traditionally difficult for AI to analyze • Works with the Sponsor’s clinical trial data, not third-party data, to
Slide 12: The Team
We have assembled a highly experienced leadership team OFFICERS George Achilleos Josh Spiegel Dr. Joseph Geraci Chief Executive Officer President Chief Technology Officer / Chief Scientific Officer and Director George is a seasoned Business Executive with 25-plus years of experience in finance, sale
Slide 13: NetraMark's focus is to improve probability of a positive clinical trial
NetraMark’s focus is to leverage a Sponsor’s clinical trial data readout to improve the probability of a positive clinical trial How do we do this?
Slide 14: The NetraMark Rapid Workflow
The NetraMark Rapid Workflow – Results in 4 to 6 weeks NetraMark ingests clinical trial data provided by the Sponsor from Phase 1 (assuming at least 30 participants), Phase 2 or Phase 3 Data preparation NetraAI Implementation NetraGPT and ingestion NetraAI’s proprietary Attractor AI NetraAI-discover
Slide 15: The Good, the Bad and the Ugly
The GOOD, the BAD and the UGLY NetraAI segments patient populations into: • The “good”: Favourable explainable outcomes • The “bad”: Unfavourable explainable outcomes A SP P R O A C H • The “ugly”: Unexplained or unpredictable outcomes By focusing on the explainable subpopulations, we are well posit
Slide 16: NetraMark Project Deliverables
NetraMark provides clinical trial enabling deliverables The NetraMark project deliverables • Identification of the specific variables, called personas, driving drug response, placebo response and adverse events • The associated P-Value for each persona • The associated Effect Size for each persona A
Slide 17: Five ways to leverage the NetraMark deliverables
Get your drug to market – five ways to leverage the NetraMark deliverables Use the discovered personas and associated variables driving placebo and drug 01 Protocol response to enrich the study population in a subsequent protocol. Enrichment Use the discovered personas and associated variables for a
Slide 18: Deal pipeline momentum
U S E C A STEH–E GDEEN A EL RPAI LPIEZLEI D N EA N X I E T Y Deal pipeline momentum
Slide 19: Commercialization routes to market
U S E C ACSOE M– MGEERNCEIRAAL LI ZI ZAT E DI OANN X I E T Y Direct Commercialization routes to market Channel Partners
Slide 20: Direct Route to Market - pipeline momentum
Direct Route to Market - pipeline momentum Industry Data E DI OANN X I E T Y Number of pharmaceutical companies with a data readout Dec 2024 to Dec 2025 in the therapeutic area – CNS or Oncology and U S E C ACSOE M– MGEERNCEIRAAL LI ZI ZAT Phase 2 or 3 • Total Phase 2 readouts – 377 • Total Phase 3
Slide 21: Direct Route to Market - pipeline momentum
Direct Route to Market - pipeline momentum Total Leads 148 Opportunities E DI OANN X I E T Y + Already Closed Deals 5 MidSize Pharma + U S E C ACSOE M– MGEERNCEIRAAL LI ZI ZAT Average Deal Value $175K USD Types of Groups in Pipeline: Large Cap ~ $100B+ Midsize ~ $1B+ Single Compound ~ less than $1B
Slide 22: Channel Partner Route to Market - pipeline momentum
Channel Partner Route to Market - pipeline momentum Highlights E DI OANN X I E T Y • Global CRO operating in 60+ countries • Under this agreement, NetraMark’s AI U S E C ACSOE M– MGEERNCEIRAAL LI ZI ZAT technology will initially be used by Worldwide for: • Phase 2 (neuroscience and oncology clinical
Slide 23: The Future – Projected Contract Backlog
The Future – Projected Contract Backlog* Future Expectations for NetraMark’s Projected Contract Backlog (Next 12 Months) • Over the next 12 months, NetraMark anticipates a significant build in its projected contract backlog, reflecting strong momentum across both direct and partner-led commercial pa
Slide 24: Regulatory Pathway
Regulatory Engagement status NetraMark is pleased to announce it has submitted a Critical Path Innovation Meeting (CPIM) request with the U.S. Food and Drug Administration (FDA): • A CPIM is a unique, non-binding exploratory dialogue opportunity for companies to engage with the FDA early in REGULATO
Slide 25: Solutions Development
Evolutionary solutions NetraMark is enhancing its base AI-powered trial solutions by developing two new offerings, grounded in its proprietary NetraAI that are leveraging insights learned from Phase 2 data readouts. 1. Patient Adjudication SOLUTIONS DEVELOPMENT AI-driven support for expert review an
Slide 26: Summary
Summary • Proprietary and Advanced Commercial ready platform • Technology built, gone through QA validation and is commercialized • Established high profile research collaborations with centers of excellence • Developed a focused market entry strategy S XIETY • Therapeutic core focus areas – CNS and
Slide 27: Thank you
Thank you For more information, please contact george@netramark.com CSE: AIAI OTCQB : AI NMF FRA: PF0
NetraMark Holdings — Investor Presentation (April 2025) on 6ix